Skip to main content

Advertisement

SpringerLink
Log in

Aromatase expression in atypical ductal hyperplasia in women

  • Brief Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Purpose

To determine the levels of aromatase in atypical ductal hyperplasia (ADH) lesions, tissue surrounding the ADH, and in dense and non-dense normal breast tissue. We postulated that excess aromatase in breast tissue might, through production of increased estrogen, drive the carcinogenic process. Estrogens and their metabolites are thought to contribute to the development of breast cancer through estrogen receptor-mediated mechanisms and genotoxic effects of estrogen metabolites. ADH is a benign lesion of the breast which is associated with substantially increased risk for subsequent development of breast cancer. After 25 years, approximately 30% of women with ADH develop breast cancer. In women with three or more separate ADH lesions at the same time, 47% will develop breast cancer over that time period. Another important risk factor for breast cancer is the presence of mammographically dense breast tissue.

Methods

We utilized quantitative immunochemical analysis of aromatase in biopsy tissue to test this possibility. Previously published results comparing dense with non-dense breast tissue in normal women (Vachon et al. Breast Cancer Res Treat 125:243–252, 2011) were used for comparisons with ADH. A well-characterized histochemical H-score was employed for quantitative assessment of aromatase in the various tissue studied.

Results

The H-score of aromatase staining was statistically significantly higher (p = 0.003) in the ADH epithelium than surrounding epithelial tissue. In order of H-score from highest to lowest were ADH, issue surrounding ADH, dense normal and non-dense normal breast tissues. The levels of aromatase in a subset of women with ADH who went on to develop breast cancer were not higher than in women who did not.

Conclusions

We suggest from these studies that overexpression of aromatase in breast tissue and its resultant increase in estradiol levels may contribute to the later development of breast cancer in women with ADH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7–30

    Article  PubMed  Google Scholar 

  2. Ozanne EM, Wittenberg E, Garber JE, Weeks JC (2010) Breast cancer prevention: patient decision making and risk communication in the high risk setting. Breast J 16(1):38–47

    Article  PubMed  Google Scholar 

  3. Ganz PA, Land SR (2008) Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer. [Review] [34 refs]. Menopause 15(4:Suppl):Suppl-803

  4. Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371–1388

    Article  CAS  PubMed  Google Scholar 

  5. Fisher MD, O’Shaughnessy J (2002) Anastrozole may be superior to tamoxifen as adjuvant treatment for postmenopausal patients with breast cancer. Clin Breast Cancer 4:269–271

    Article  Google Scholar 

  6. Tchou J, Hou N, Rademaker A, Jordan VC, Morrow M (2004) Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer 100(9):1800–1806

    Article  PubMed  Google Scholar 

  7. Visvanathan K, Hurley P, Bantug E et al (2013) Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. [Review][Erratum appears in J Clin Oncol. 2013 Dec 1;31(34):4383]. J Clin Oncol 31(23):2942–2962

    Article  PubMed  Google Scholar 

  8. Hartmann LC, Degnim AC, Santen RJ, Dupont WD, Ghosh K (2015) Atypical hyperplasia of the breast–risk assessment and management options. N Engl J Med 372(1):78–89

    Article  PubMed  PubMed Central  Google Scholar 

  9. Hartmann LC, Radisky DC, Frost MH et al (2014) Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prev Res 7(2):211–217

    Article  CAS  Google Scholar 

  10. Page DL, Dupont WD, Rogers LW, Rados MS (1985) Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 55(11):2698–2708

    Article  CAS  PubMed  Google Scholar 

  11. Degnim AC, Dupont WD, Radisky DC et al (2016) Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women. Cancer 122(19):2971–2978

    Article  PubMed  PubMed Central  Google Scholar 

  12. Allred DC, Mohsin SK, Fuqua SA (2001) Histological and biological evolution of human premalignant breast disease. Endocr-Relat Cancer 8(1):47–61

    Article  CAS  PubMed  Google Scholar 

  13. Barr FE, Degnim AC, Hartmann LC et al (2011) Estrogen receptor expression in atypical hyperplasia: lack of association with breast cancer. Cancer Prev Res 4(3):435–444

    Article  Google Scholar 

  14. Shoker BS, Jarvis C, Clarke RB et al (1999) Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol 155(6):1811–1815

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Shoker BS, Jarvis C, Clarke RB et al (2000) Abnormal regulation of the oestrogen receptor in benign breast lesions. J Clin Pathol 53(10):778–783

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Shoker BS, Jarvis C, Sibson DR, Walker C, Sloane JP (1999) Oestrogen receptor expression in the normal and pre-cancerous breast. J Pathol 188(3):237–244

    Article  CAS  PubMed  Google Scholar 

  17. Santen R, Pinkerton J (2002) Benign breast disorders. In: DeGroot LJ, Jameson JL (eds) Endocrinology. W.B. Saunders Company, Philadelphia, pp 2189–2198

  18. Santen RJ, Mansel R (2005) Benign breast disorders. [Review] [89 refs]. N Engl J Med 353(3):275–285

    Article  CAS  PubMed  Google Scholar 

  19. Yue W, Wang JP, Li Y et al (2010) Effects of estrogen on breast cancer development: role of estrogen receptor independent mechanisms. Int J Cancer 127(8):1748–1757

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE (1990) Increased cell division as a cause of human cancer. Cancer Res 50(23):7415–7421

    CAS  PubMed  Google Scholar 

  21. Jefcoate CR, Liehr JG, Santen RJ et al (2000) Tissue-specific synthesis and oxidative metabolism of estrogens. J Natl Cancer Inst Monogr 27:95–112

    Article  CAS  Google Scholar 

  22. Lavigne JA, Helzlsouer KJ, Huang HY et al (1997) An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res 57(24):5493–5497

    CAS  PubMed  Google Scholar 

  23. Yager JD, Liehr JG (1996) Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 36:203–232

    Article  CAS  PubMed  Google Scholar 

  24. Yager JD (2000) Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr 27:67–73

    Article  CAS  Google Scholar 

  25. Wood LD, Parsons DW, Jones S et al (2007) The genomic landscapes of human breast and colorectal cancers.[see comment]. Science 318(5853):1108–1113

    Article  CAS  PubMed  Google Scholar 

  26. Leary RJ, Lin JC, Cummins J et al (2008) Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci USA 105(42):16224–16229

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. O’Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC (1998) Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 90(9):697–703

    Article  PubMed  Google Scholar 

  28. Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ (1998) Mammographic densities and breast cancer risk. Cancer Epidemiol Biomark Prev 7(12):1133–1144

    CAS  Google Scholar 

  29. Boyd NF, Jensen HM, Cooke G, Han HL, Lockwood GA, Miller AB (2000) Mammographic densities and the prevalence and incidence of histological types of benign breast disease. Reference Pathologists of the Canadian National Breast Screening Study. Eur J Cancer Prev 9(1):15–24

    Article  CAS  PubMed  Google Scholar 

  30. Santen RJ, Boyd NF, Chlebowski RT et al (2007) Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. [Review] [95 refs]. Endocr Relat Cancer 14(2):169–187

    Article  PubMed  Google Scholar 

  31. Vachon CM, Sasano H, Ghosh K et al (2011) Aromatase immunoreactivity is increased in mammographically dense regions of the breast. Breast Cancer Res Treat 125(1):243–252

    Article  CAS  PubMed  Google Scholar 

  32. Page DL, Rogers LW (1992) Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum Pathol 23(10):1095–1097

    Article  CAS  PubMed  Google Scholar 

  33. Berg JC, Visscher DW, Vierkant RA et al (2008) Breast cancer risk in women with radial scars in benign breast biopsies. Breast Cancer Res Treat 108(2):167–174

    Article  PubMed  Google Scholar 

  34. Sasano H, Miki Y, Shibuya R, Suzuki T (2010) Aromatase and in situ estrogen production in DCIS (ductal carcinoma in situ) of human breast. J Steroid Biochem Mol Biol 118(4–5):242–245

    Article  CAS  PubMed  Google Scholar 

  35. Sasano H, Anderson TJ, Silverberg SG et al (2005) The validation of new aromatase monoclonal antibodies for immunohistochemistry—a correlation with biochemical activities in 46 cases of breast cancer. J Steroid Biochem Mol Biol 95(1–5):35–39

    Article  CAS  PubMed  Google Scholar 

  36. Santen RJ, Martel J, Hoagland M et al (1994) Stromal spindle cells contain aromatase in human breast tumors. J Clin Endocrinol Metab 79(2):627–632

    CAS  PubMed  Google Scholar 

  37. Sasano H, Suzuki T, Nakata T, Moriya T (2006) New development in intracrinology of breast carcinoma. [Review] [54 refs]. Breast Cancer 13(2):129–136

    Article  PubMed  Google Scholar 

  38. Takagi K, Ishida T, Miki Y et al (2013) Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment. Br J Cancer 109(1):100–108

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Shibuya R, Suzuki T, Miki Y et al (2008) Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast. Endocr Relat Cancer 15(1):113–124

    Article  CAS  PubMed  Google Scholar 

  40. Ritte R, Lukanova A, Tjonneland A et al (2013) Height, age at menarche and risk of hormone receptor-positive and -negative breast cancer: a cohort study. Int J Cancer 132(11):2619–2629

    Article  CAS  PubMed  Google Scholar 

  41. Yue W, Wang JP, Li Y et al (2010) Effects of estrogen on breast cancer development: role of estrogen receptor independent mechanisms. Int J Cancer 127(8):1748–1757

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Santen RJ, Yue W, Heitjan DF (2012) Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy. Cancer Epidemiol Biomark Prev 21(7):1038–1048

    Article  CAS  Google Scholar 

  43. Dupont WD, Parl FF, Hartmann WH et al (1993) Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 71(4):1258–1265

    Article  CAS  PubMed  Google Scholar 

  44. Dupont WD, Page DL, Parl FF et al (1999) Estrogen replacement therapy in women with a history of proliferative breast disease. Cancer 85(6):1277–1283

    Article  CAS  PubMed  Google Scholar 

  45. Page DL, Dupont WD (1998) Benign breast diseases and premalignant breast disease. Arch Pathol Lab Med 122(12):1048–1050

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study has been supported by two NIH Grants, NCI CA187112 to Dr. Amy Degnim and R21 CA 186734 to Dr. Celine Vachon.

Author information

Authors and Affiliations

  1. University of Virginia Health Sciences System, Charlottesville, VA, USA

    R. J. Santen

  2. Mayo Clinic, Jacksonville, FL, USA

    D. C. Radisky

  3. Mayo Clinic, Rochester, MN, USA

    A. Degnim, M. H. Frost, C. M. Vachon & K. Ghosh

  4. Tohoku University School of Medicine, Sendai, Japan

    F. Guestini, K. M. McNamara & H. Sasano

Authors
  1. R. J. Santen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. C. Radisky
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Degnim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. H. Frost
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. M. Vachon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K. Ghosh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F. Guestini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K. M. McNamara
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H. Sasano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. J. Santen.

Ethics declarations

Conflict of interest

None of the authors has reported conflicts of interest with respect to the information covered in this manuscript

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Santen, R.J., Radisky, D.C., Degnim, A. et al. Aromatase expression in atypical ductal hyperplasia in women. Breast Cancer Res Treat 163, 623–629 (2017). https://doi.org/10.1007/s10549-017-4184-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-017-4184-x

Keywords

Search

Navigation